Detroit-based Caraco Pharmaceutical Laboratories Ltd. (NYSE Amex: CPD) said Wednesday that it had started shipping bupropion hydrochloride extended release tablets.
This product was recently approved by the United States Food and Drug Administration for an Abbreviated New Drug Application of Caraco parent Sun Pharma.
These bupropion hydrochloride extended release tablets, 100 mg, 150 mg, and 200 mg, are therapeutically equivalent to GlaxoSmithKline’s Wellbutrin SR Extended Release tablets. These strengths of generic bupropion hydrochloride extended release tablets have annual sales of approximately $300 million in the U.S.
The drug is used to treat depression.
Caraco develops, manufactures, markets and distributes generic pharmaceuticals to the nation’s largest wholesalers, distributors, drugstore chains and managed care providers.
More at www.caraco.com.
(c) 2010, WWJ Newsradio 950. All rights reserved.